Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment.
Leutz A, Pinter A, Thaçi D, Augustin M, Schuster C, Fotiou K, Hundemer HP, Saure D, Mrowietz U, Reich K. Leutz A, et al. Among authors: fotiou k. Br J Dermatol. 2021 Mar;184(3):548-550. doi: 10.1111/bjd.19558. Epub 2020 Nov 10. Br J Dermatol. 2021. PMID: 32940343 No abstract available.
Ixekizumab im Vergleich zu Fumarsäureestern und Methotrexat bei der Behandlung der Nagelpsoriasis bei Patienten mit mittelschwerer bis schwerer Psoriasis: Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis.
Augustin M, Mrowietz U, Willsmann-Theis D, Gerdes S, Fotiou K, Schuster C, Mert C, Holzkaemper T, Behrens F, Pinter A. Augustin M, et al. Among authors: fotiou k. J Dtsch Dermatol Ges. 2024 Feb;22(2):278-282. doi: 10.1111/ddg.15292_g. J Dtsch Dermatol Ges. 2024. PMID: 38361190 No abstract available.
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
Pinter A, Eyerich K, Costanzo A, Garrelts A, Schuster C, Mert C, Lampropoulou A, Fotiou K, Maul JT, Papp KA. Pinter A, et al. Among authors: fotiou k. J Dermatolog Treat. 2024 Dec;35(1):2350227. doi: 10.1080/09546634.2024.2350227. Epub 2024 May 26. J Dermatolog Treat. 2024. PMID: 38797734 Free article.
Serum ceruloplasmin as a marker in prostate cancer.
Fotiou K, Vaiopoulos G, Lilakos K, Giannopoulos A, Mandalenaki K, Marinos G, Koritsiadis G, Sourdis J, Konstantinidou E, Konstantopoulos K. Fotiou K, et al. Minerva Urol Nefrol. 2007 Dec;59(4):407-11. Minerva Urol Nefrol. 2007. PMID: 17947957